- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.01. | Senti Biosciences, Inc.: Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation | 3 | GlobeNewswire (USA) | ||
| SENTI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 18.12.25 | Senti Biosciences, Inc.: Senti Biosciences Announces New Employment Inducement Grants | 3 | GlobeNewswire (USA) | ||
| 09.12.25 | Why Is Gene Therapy Focused Senti Bio Stock Falling Today? | 13 | Benzinga.com | ||
| 09.12.25 | Senti Biosciences Secures FDA RMAT Designation For SENTI-202 | 1 | RTTNews | ||
| 09.12.25 | Positive Studiendaten zur Krebstherapie beflügeln Senti Bio-Aktie | 20 | Investing.com Deutsch | ||
| 09.12.25 | Senti Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.25 | Leerink Partners startet Coverage für Senti Biosciences mit "Outperform" | 2 | Investing.com Deutsch | ||
| 21.11.25 | Leerink Partners initiates coverage on Senti Biosciences stock with Outperform rating | 1 | Investing.com | ||
| 13.11.25 | Senti Biosciences GAAP EPS of -$0.69 misses by $0.12 | 9 | Seeking Alpha | ||
| 13.11.25 | Senti Bio to present updated clinical data on SENTI-202 at ASH meeting | 2 | Investing.com | ||
| 13.11.25 | Senti Bio präsentiert aktualisierte klinische Daten zu SENTI-202 auf Jährlicher ASH-Tagung | 1 | Investing.com Deutsch | ||
| 13.11.25 | Senti Biosciences, Inc.: Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual ... | 175 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene... ► Artikel lesen | |
| 13.11.25 | Senti Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11.25 | Senti Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11.25 | Senti Biosciences, Inc.: Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025 | 1 | GlobeNewswire (USA) | ||
| 14.10.25 | Senti Biosciences stock rating initiated at Buy by H.C. Wainwright | 10 | Investing.com | ||
| 14.10.25 | Senti Biosciences: H.C. Wainwright startet Coverage mit Kaufempfehlung | 6 | Investing.com Deutsch | ||
| 06.10.25 | Senti Biosciences, Inc.: Senti Bio to Present at BioJapan | 1 | GlobeNewswire (USA) | ||
| 12.08.25 | Senti Biosciences, Inc.: Senti Bio Participates in Virtual Investor "What This Means" Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia | 1 | GlobeNewswire (USA) | ||
| 07.08.25 | Senti Biosciences, Inc.: Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 | 673 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,148 | +0,79 % | Evotec-Aktie: Hat sie über +50% Potenzial? | Mit einem Kursgewinn von +7% ist die Evotec-Aktie am Dienstagmorgen einsamer Spitzenreiter im TecDAX. Was gibt dem Wirkstoffforschungsunternehmen Rückenwind und können sich Anleger auf eine nachhaltige... ► Artikel lesen | |
| MEDIGENE | 0,042 | -8,26 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 43,170 | -0,70 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| VALNEVA | 3,986 | +0,61 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| STRYKER | 302,10 | -0,33 % | Stryker Corporation: Stryker declares an $0.88 per share quarterly dividend | Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders... ► Artikel lesen | |
| ILLUMINA | 101,04 | -0,18 % | Illumina Inc. Q4 Profit Advances | SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) released earnings for its fourth quarter that Increases, from the same period last yearThe company's bottom line came in at $334 million, or $2.16... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 41,200 | -0,48 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 662,80 | -0,27 % | REGENERON PHARMACEUTICALS, INC. - 10-K, Annual Report | ||
| BRAIN BIOTECH | 2,240 | +0,90 % | Brain Biotech: Kursziel der Aktie wird gestutzt | Die Analysten der Deutschen Bank bezeichnen die jüngsten Zahlen von Brain Biotech als Enttäuschung. 2024/2025 sinkt der Umsatz von 54,6 Millionen Euro auf 49,6 Millionen Euro. Für das neue Geschäftsjahr... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,339 | +1,14 % | Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected | PETAH TIKVA (dpa-AFX) - This week's biotech landscape witnessed key FDA meetings being scheduled, IND clearances, complete response letters, sale of oncology assets and clinical trial data readouts... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,745 | -1,29 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity | Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed
VK2735 Currently Being Evaluated in... ► Artikel lesen | |
| BAVARIAN NORDIC | 26,050 | +0,19 % | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program | ||
| INTELLIA THERAPEUTICS | 10,320 | -0,53 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TEMPUS AI | 46,600 | 0,00 % | Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones | ||
| BIO-GATE | 0,630 | +1,61 % | BIO-GATE AG: Aktuelle Schwäche im Fokus |
SENTI BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,945 Euro und damit +14,91 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SENTI BIOSCIENCES INC finden Sie auf Wallstreet Online.